#eisai — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #eisai, aggregated by home.social.
-
Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to approaching the brain-wasting disease as a system of complex pathways. https://www.japantimes.co.jp/news/2025/12/12/world/science-health/alzheimers-trials-shift-approach/?utm_medium=Social&utm_source=mastodon #worldnews #sciencehealth #aging #dementia #alzheimer039s #pharmaceuticals #medicine #eisai #novonordisk
-
Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled in one of the biggest medical controversies in recent years. https://www.japantimes.co.jp/news/2024/09/21/world/science-health/alzheimers-drugs-controversy/ #worldnews #sciencehealth #dementia #aging #alzheimer039s #eisai #biogen #elililly #drugs #medicine #brain
-
European Medicines Agency approves 14 new medicines but rejects new Alzheimer’s drug https://www.euractiv.com/section/health-consumers/news/european-medicines-agency-approves-14-new-medicines-but-rejects-new-alzheimers-drug/?utm_source=dlvr.it&utm_medium=mastodon #AlzheimersDisease #Biogen #Eisai #Leqembi #novonordisk
-
Gilead’s Trodelvy stumbles in late-stage trials but remains prized cancer asset—BMS axes Eisai ADC pact 3 years after paying $650M for would-be Elahere rival —Supreme Court’s Chevron Doctrine ruling could limit FDA’s regulatory authority—http://bit.ly/w28kSd #gileadsciences #cancer #antibodydrugconjufate #eisai #bristolmyerssquibb #supremecourt #fda #chevrondoctrine #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
-
Moderna’s COVID-Flu combo shot beats separate vaccines in phase III study—FDA accepts Eisai's subcutaneous Leqembi filing, sets January 25 decision date — Boehringer, Lilly face off in MASH at EASL—http://bit.ly/w28kSd #moderna #vaccines #flu #covid19 #alzheimers #fda #eisai #biogen #elililly #mash #easl #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
-
Novo Nordisk owner buys majority stake in Austrian life science tools company—As sales of weight loss drugs skyrocket, the insulin market falters —Eisai starts rolling submission for injectable version of Alzheimer's drug with FDA --http://bit.ly/w28kSd #novonordisk #mergersandacquisitions #insulin #diabetes #alzheimers #eisai #biogen #fda #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
-
Nine months into the U.S. launch of the first drug proven to slow the advance of Alzheimer's, Eisai and Biogen's Leqembi is facing an unexpected hurdle to widespread use. https://www.japantimes.co.jp/news/2024/04/24/world/science-health/alzheimer-drug-us-adoption-slow/ #worldnews #sciencehealth #alzheimers #brain #eisai #biogen #leqembi #us
-
Biogen and Eisai fall behind on Leqembi’s subcutaneous BLA for Alzheimer’s—Teva, Viatris win new chance to challenge J&J schizophrenia drug patent—3M spins out Solventum--http://bit.ly/w28kSd #biogen #eisai #alzehimers #teva #jnj #patents #schizophrenia #3m #spinoffs #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
-
New Alzheimer's drug lecanemab will cost around ¥2.98 million per year in Japan, but will be largely covered by public health insurance that will limit the burden for patients to between 10% and 30% of that cost, subject to a cap, a health ministry body has said. https://www.japantimes.co.jp/news/2023/12/13/japan/eisai-biogen-alzheimers-drug-price/?utm_content=buffer4dd52&utm_medium=social&utm_source=mastodon&utm_campaign=bffmstdn #japan #alzheimer039s #drugs #eisai #biogen #pharmaceuticals
-
Some doctors said its effect on the disease may not be clinically meaningful enough when weighed against the risk of brain swelling, its likely high price. https://www.japantimes.co.jp/news/2023/06/19/world/science-health-world/europe-alzheimers-experts-doubt-eisai-biogen-drug/?utm_content=buffer28b58&utm_medium=social&utm_source=mastodon&utm_campaign=bffmstdn #news #worldnews #health #brain #alzheimers #biogen #eisai
-
FDA approves new Alzheimer’s treatment despite risks, unclear benefits - Enlarge / MRI of a human brain. (credit: Getty | BSIP)
The Foo... - https://arstechnica.com/?p=1908494 #cognitivedecline #alzheimers #treatment #antibody #approval #science #biogen #eisai #fda
